FDA emergency use submission delayed to Q4
FDA emergency use submission delayed to Q4
Novavax announced that it will delay the submission of its Covid-19 vaccine to the Food and Drug Administration for emergency use authorization until its fourth quarter.
Shares of the biotechnology company slipped 10% after the bell.
The company has filed for regulatory approval in India, Indonesia and the Philippines. Plans to submit the vaccine for emergency use listing at the World Health…
Discover more from USNewsRank
Subscribe to get the latest posts sent to your email.